STAT+: A political contest in the U.K. could shake up drug pricing

STAT PlusNewsletterThe Readout A political contest in the U.K. could shake up drug pricing Makary and Cassidy’s fates, U.S. pressures Germany to pay more for drugs, and other health news Manage alerts for this article Email this article Share this article By Elaine ChenMay 15, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on making it to the end of the week!Advertisement U.S. officials pressured Germany to pay more for drugs Trump administration officials told the German ambassador to the United States at a recent meeting that the European country should pay more for medicines, according to a person familiar with the encounter. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended D.C. Diagnosis May 14, 2026 STAT Plus: The hunt for FDA’s next leader The Readout May 14, 2026 STAT Plus: BeOne wins FDA approval in lymphoma race Advertisement Health Tech Newsletter May 14, 2026 STAT Plus: Why big digital health players are missing from Medicare’s chronic care experiment Biotech May 14, 2026 STAT Plus: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study Exclusive May 14, 2026 STAT Plus: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million Subscriber Picks